OSSM-007

**OSSM-007** is a cryopreserved, interferon-gamma (IFN-γ)-primed allogeneic bone marrow-derived mesenchymal stem cell (BM-MSC) product developed by Ossium Health for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD), a severe complication following allogeneic hematopoietic stem cell transplants affecting 30-60% of recipients, with ~50% becoming steroid-refractory and facing 80% mortality due to limited options. The IFN-γ priming enhances the immunomodulatory potency and manufacturing consistency of MSCs, which exert therapeutic effects via suppression of donor T-cell alloreactivity, promotion of regulatory T cells, and inhibition of pro-inflammatory cytokines without broad immunosuppression. Sourced from Ossium's deceased donor bone marrow bank, it supports repeated high-dose intravenous administration; preclinical data confirm safety, biodistribution, and persistence in mice, with CIRM funding ($3.46M CLIN1 grant in 2023) accelerating IND-enabling studies toward Phase 1 trials in adults.[1][4][7][10]

Other names

mesenchymal stem cellsIFN-gamma primed mesenchymal stem cellsOssium MSCsinterferon-gamma primed mesenchymal stem cells